Market Highlights:
Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi, and parasites change when they are exposed to antimicrobial drugs. Antibiotic drugs include antibiotics, antifungals, antivirals, antimalarials, and anthelmintic.
According to MRFR analysis, the global Antibiotic Resistance Market Growth is expected to register a CAGR of 5.8% during the forecast period of 2019 to 2025 and was valued at USD 8,120 million in 2018.
The growth of global antibiotic resistance market is driven by various factors such as -Rising antibiotic drug resistance infections, rise in the incidence of chronic and infectious disease, increase in clinical developments of antibiotic resistance, and rise in global initiatives to control drug-resistance.
Several market players currently dominate the global antibiotic resistance market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Key Players:
• Achaogen
• MELINTA THERAPEUTICS
• Nabriva Therapeutics plc
• PARATEK therapeutics
• Seres Therapeutics
• Theravance Biopharma
• Tetraphase Pharmaceuticals
• Basilea Pharmaceutica Ltd
• Entasis Therapeutics
• NEMESIS BIOSCIENCE LTD
• Procarta Biosystems
• Allecra Therapeutics
Segmentation:
• The global antibiotic resistance market has been segmented based on drug class, disease, pathogen, and end user.
• The market, based on drug class, has been divided into cephalosporins, Combination therapies, tetracyclines, lipoglycopeptides, oxazolidinones, and others. The combination therapies segment is likely to be the largest growth during the review period due to the increased usage of these therapies for gram-negative infections.
• The global antibiotic resistance market has been bifurcated, based on disease, into complicated urinary tract infections, bloodstream infections, complicated intra-abdominal infections, clostridium difficile infections, acute bacterial and skin structure infections, hospital-acquired bacterial pneumonia/ventilator, community-acquired bacterial pneumonia, and others.
• The global antibiotic resistance market has been segmented based on pathogen into staphylococcus aureus, streptococcus pneumoniae, acinetobacter, enterococcus, Hemophilus influenzae, pseudomonas aeruginosa, clostridium difficile, K. pneumoniae, campylobacter, and others.
• The end user segment of the antibiotic resistance market includes hospitals & clinics, research organizations, and others.
Regional Analysis:
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the rising growth in the pharmaceutical sector. The antibiotic resistance market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European antibiotic resistance market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The antibiotic resistance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Increasing healthcare expenditure has boosted the growth of the antibiotic resistance market; the market in Asia-Pacific is expected to be the fastest-growing. The antibiotic resistance market in the Middle East & Africa has been divided into the Middle East and Africa.